


2019

medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



MEDICINA

Volumen 79, Supl. IV, págs. 1-338

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina

José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos

Aires, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Rodolfo S. Martin
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina

Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina

Rodolfo C. Puche
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina

Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires,

Argentina

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: **Fundación Revista Medicina**

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,

1427 Buenos Aires, Argentina

Tel. 5287-3827 Int. 73919 y 4523-6619

e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina de Ciencia y
Tecnología de Animales de Laboratorio (AACyTAL)**

**con la participación de
The Histochemical Society**

13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

Abstract/Resumen: Objective: To improve prescriptive behavior in medical professionals of a Social Security Institute in Corrientes. A quasi-experimental study was conducted, without a control group. All application forms for extended treatment plans in a Social Service Institute of Corrientes were analyzed during a period of six months before and after an educational intervention during the year 2018-2019. The variables analyzed were: gender, age, diagnoses, prescribed medications, medication errors. To describe the types of errors the taxonomy of Otero Lopez was used. Were analyzed 600 application forms and 293 (49 %) prescription errors were observed during the prescription phase. Seventy seven percent (n= 150) of the patients were male, average age 52 years (range 5-91 years). The most frequent error detected before the intervention was prescription of erroneous medication (99 %) grouped as follows: a) inappropriate medications: meloxicam + glucosamine (5), ranitidine + domperidone (7), ergotamine + ibuprofen + caffeine (6), bromazepam + clobopride + simethicone (2), trimebutin + pancreatin + simethicone (7), denosumab (3), fexubostat (2); omega 3 (10), deproteinized extract of calf blood (2), donepezil (4), memantine (3); b) unnecessary medication: aspirin (15), rosuvastatin (9), omeprazole (8). Post-intervention results: only 4 errors were observed in the 600 application forms: inappropriate medications meloxicam + glucosamine (1), memantine (1), pancreatin + simethicone + trimebutin (1); unnecessary medication: aspirin (2). Through educational intervention an improvement in the prescriptive behavior was observed, especially those medications considered inappropriate, improving patient safety and quality of care.

0612 - CLASSIC HISTAMINE H1 RECEPTOR INVERSE AGONISTS ACTIVATE ERK1/2 PATHWAY AND MODULATE THE TRANSCRIPTION OF INFLAMMATORY GENES

Valeria BURGHI (1) | Daniel ZAPPÍA(1) | Sonia RIPOLL(1) | Emiliana ECHEVERRÍA(1) | Carina Claudia SHAYO(2) | Federico MONCZOR(1) | Natalia FERNÁNDEZ(1)

ININFA, UBA-CONICET (1); IBYME-CONICET (2)

Abstract/Resumen: Recently, we showed that widely used histamine H1 receptor (H1R) ligands that exert therapeutic actions by blocking the effects of histamine (HA), display positive efficacy concerning receptor desensitization and/or internalization. Now we aimed to investigate whether these processes affect the modulation of pro-inflammatory genes and its relationship with the activation of other signaling pathways independent from G protein. While 3 h (long term) exposure to antihistamines decreased expression of pro-inflammatory genes, when we exposed A549 cells to HA, chlorpheniramine (CHLOR) or diphenhydramine (DIPH) for 10 min (short term) and ligands were removed, ciclooxigenase 2 (COX-2) and interleukin 8 (IL-8) mRNA levels were increased after 2h 50 min (among 40 and 100 % for all ligands, $p < 0.05$). Consistently, ERK1/2 phosphorylation levels were increased by HA (373 ± 102 %), CHLOR (95 ± 30 %) and DIPH (56 ± 16 %), $p < 0.05$, indicating that they display positive efficacy towards this signaling pathway that has been described to be involved in regulation of both genes. When A549 cells were pre-exposed for 3 h with these ligands and after 1 h recovery, were stimulated with HA for 10 min, we found lower COX-2 mRNA levels compared to those observed without pretreatment (HA 29.5 ± 0.5 %, CHLOR 40.5 ± 16.5 and DIPH 34 ± 8.8 % of reduction, $p < 0.05$). We also found lower IL-8 mRNA levels in CHLOR and DIPH pretreated samples (both around 20 % of reduction, $p < 0.05$) although no differences were observed in HA pretreated cells. Thus, although short term exposure to antihistamines increase pro-inflammatory genes expression, a prolonged exposure with these ligands diminished it and impaired the increase induced by HA indicating that their anti-inflammatory effects continue despite the ligands being removed. In all, these findings reinforce the biased nature of these ligands and claim for a correct classification, providing evidence for a more rational and safe use of antihistamines.

0630 - THE ANTIALLODYNIC EFFECTS OF INTRATHECALLY APPLIED IMT504 ARE RELATED TO MODULATION OF GLIAL/MICROGLIAL RESPONSES AND OF THE EXPRESSION OF INFLAMMATORY FACTORS IN RATS WITH HINDPAW INFLAMMATION

Candelaria LEIGUARDA (1) | Constanza POTILINSKI (1) | Harry TRIGOSSO-VENARIO(2) | Luis CONSTANDIL*(3) | Pablo BRUMOVSKY*(1)

INSTITUTO DE INVESTIGACIONES EN MEDICINA TRASLACIONAL, CONICET-UNIVERSIDAD AUSTRAL (1); HOSPITAL UNIVERSITARIO AUSTRAL (2); LABORATORIO DE NEUROBIOLOGÍA, FACULTAD DE QUÍMICA Y BIOLÓGIA, UNIVERSIDAD DE SANTIAGO DE CHILE (3)

Abstract/Resumen: Chronic immune diseases, pathogenic infection, or tissue injury are common medical conditions, often leading to the development of chronic inflammatory pain which is unfortunately difficult to treat and often unresponsive to conventional therapies. We recently showed that the oligodeoxynucleotide IMT504 has remarkable antialloodynic and anti-inflammatory effects upon systemic administration in rats undergoing unilateral hindpaw chronic inflammation. In this study, we addressed if IMT504 intrathecal (i.t.) delivery is capable of modulating mechanical allodynia and its underlying mechanisms of action in the spinal cord. Male Sprague-Dawley rats with complete Freund's adjuvant (CFA)-induced unilateral hindpaw inflammation, received an acute i.t. injection of IMT504 ($2 \mu\text{g}/\mu\text{l}$; $10 \mu\text{l}$). C-reflex, wind-up and mechanical hyperalgesia were recorded during 72 h after injection. Spinal cords were processed for immunofluorescence or western blot analysis for markers of activated glia and microglia such as fibrillary acidic protein (GFAP) and integrin αM (OX42), toll-like receptor 4 (TLR-4) and NF- κB p65 subunit. Intrathecal IMT504 induced a clear reduction in mechanical hyperalgesia starting 1 h and lasting 48 h after administration, in association with parallel progressive reductions in C-reflex and wind-up responses. Furthermore, IMT504 significantly downregulated the expression of GFAP, OX42, TLR4 and NF- κB . Altogether, we show that i.t. IMT504 efficiently eliminates inflammatory mechanical hyperalgesia for at least 24 h, in association with a depression in spinal sensitization and reductions in the activation of glia, microglia, and the NF- κB and TLR-4 pathways. The exact mechanisms, by which these different events relate to explain the antihyperalgesic effects of IMT504, remain to be demonstrated. However, it could be hypothesized that the net effect of IMT504 are reductions in the synthesis of spinal pro-inflammatory mediators.

0670 - DUAL MODULATION OF GLUCOCORTICOID RECEPTOR ACTIVITY BY HISTAMINE H2 RECEPTOR SIGNALING. INVOLVEMENT OF RAP, ERK AND CAMP.

Valeria Nora TORRALBA AGU (1) | Agustina Soledad KELLY(1) | Natalia Cristina FERNÁNDEZ(1) | Carlos Alberto DAVIO(1) | Carina Claudia SHAYO(2) | Carlos Daniel ZAPPÍA(1) | Federico MONCZOR(1)

ININFA, UBA-CONICET (1); INSTITUTO DE BIOLÓGIA Y MEDICINA EXPERIMENTAL (IBYME-CONICET) (2)

Abstract/Resumen: There are reports describing the interaction between membrane G-protein coupled receptor signaling and glucocorticoid receptor (GR) transcriptional activity. We have already reported that the signaling of the G alpha s-coupled histamine H2 receptor (H2r) increased GR transcriptional activity. The aim of the present work was to study the molecular mechanisms of this effect. HEK293 cells were transfected with plasmids coding to H2r, GR and a GR-driven reporter gene TAT3-Luc. While pretreatment with $10 \mu\text{M}$ amthamine, an H2r agonist which augments cAMP levels, increased dexamethasone (dex)-induced GR activity in a 50 % ($p < 0.05$), raising cAMP levels with